| References |
Lu et al., 2002: Lu X, Clements JD, Katz JM. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine. 2002; 20(7-8); 1019-1029. [PubMed: 11803061].
NCT00090688: Clinicaltrials.gov [https://www.clinicaltrials.gov/study/NCT00090688]
Riddle et al., 2020: Riddle MS, Maciel M Jr, Porter CK, Poole ST, Gutierrez RL, Gormley R, Laird RM, Sebeny PJ, Dori KE, Greenleaf ME, Hoq F, Turiansky GW, Jarell A, Hawk D, Tribble D, Savarino SJ. A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. Vaccine. 2020; 38(45); 7040-7048. [PubMed: 32978003].
|
